Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostics Rapidly Gain Ground in Infectious Diseases Sector

By LabMedica International staff writers
Posted on 22 Dec 2014
According to a new Frost & Sullivan (Mountain View, CA, USA) analysis, convergence of immunological and molecular tests will help meet growing needs for infectious disease (ID) diagnostics. More...
Although these tests remain expensive, their efficiency and accuracy strengthen their use case.

Frost & Sullivan’s new report “Analysis of the Global Infectious Disease Diagnostics Market” finds the market earned USD 7.91 billion revenue in 2013 and estimates it to reach USD 12.77 billion in 2018. Hepatitis B, hepatitis C, tuberculosis, and sepsis tests are predicted to be the major revenue generators.

The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular ID-diagnostics is growing fastest, clocking a compound annual growth of 15.3%. “Immunodiagnostics is another segment that continues to expand rapidly owing to cost-effective tests as well as the prevalence of hospital-acquired infections like sepsis and MRSA,” said Frost & Sullivan life sciences industry analyst Aish Vivekanandan, “Molecular methods and immunodiagnostics are expected to complement each other as the need for accurate and rapid diagnostic tests rises.”

Unique disease outbreaks across the globe are further escalating the demand for screening, spurring the ID diagnostic market. While decentralized and rapid tests are a growing trend in the developed world, stringent regulations complicate product development and marketing, and high costs affect the market in developing countries. Another challenge is low product awareness across regions. Companies must invest in clinical studies to prove the efficacy of their products and raise awareness among evidence-driven consumers, especially in the clinical field.

“Many participants are focusing their research on top industry requirements such as product automation, rapidity, specificity, and accuracy,” noted Vivekanandan, “Companies are also striving to expand the scope of diseases their products cover in order to establish their foothold in the global ID diagnostics market.”

The new report is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program. Related studies include: “Global in Vitro Diagnostics Market,” “US Hematology Diagnostics Market,” “Global Next-generation Sequencing Market,” and “Western European Companion Diagnostics Market.” All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Related Links:
Frost & Sullivan
Analysis of the Global Infectious Disease Diagnostics Market report
Life Sciences Growth Partnership Service program



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.